Drug news

Adventrx Pharma discontinues Exelbine for Non Small Cell Lung Cancer

Read time: 1 mins

Last updated:4th Oct 2011

Published:4th Oct 2011

Source: Pharmawand

Meetings between Adventrx Pharma and the FDA were not productive regarding the FDA Complete Response Letter and Adventrx has decided to focus its capital on its other compounds, ANX-188 and ANX-514, which reflect larger market opportunities. The company will discontinue its Exelbine programme until it finds a partner or outside investor.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

European Commission approves Takhzyro (lanadelumab) to include children with hereditary angioedema (HAE) as young as 2 years of age

The European Commission has expanded the approval of Takhzyro (lanadelumab) to include children with hereditary angioedema (HAE) as young as 2 years of age

1 mins

Drug news

Medtronic launches Penditure LAA exclusion system in the United States

Medtronic announced the United States launch of the Penditure left atrial appendage (LAA) exclusion system, an implantable clip preloaded on a single-use delivery system for LAA management during concomitant cardiac surgery procedures

1 min

Drug news

Positive results from DREAMM-7 head-to-head phase III trial for Blenrep (belantamab mafodotin) in relapsed/refractory multiple myeloma

GSK plc announced positive headline results from a planned interim efficacy analysis of the DREAMM-7 head-to-head phase III trial evaluating belantamab mafodotin as a second-line treatment for relapsed or refractory multiple myeloma

1 min

See all news